Clinical Trials Arena August 12, 2024
Spectral is already making plans for post FDA-approval, partnering with Baxter for commercialisation duties.
Spectral Medical has reported a 54% rise in revenue for the second quarter as the Canadian company looks ahead to the completion of a confirmatory trial for its septic shock treatment, Toraymyxin.
Spectral notched up $471,000 in revenue, up from $306,000 in the same period last year. Loss for the quarter was $4.4m, a $0.02 per share decrease compared to a loss of $4.2m from Q2 last year. Cash reserves were solidified with funding, with $7.5m now in the coffers compared with just under $3m available at the end of 2023.
Shares in the Toronto Stock Exchange-listed company opened 3% higher on 12 August compared to...
Today's Sponsors
Today's Sponsor